SCHEMBL30361171

CC(=O)N[C@H]1[C@H](O[C@@H]2[C@H](O[C@]3(C(=O)O)C[C@H](O)[C@@H](NC(C)=O)[C@H]([C@H](O)[C@H](O)CO)O3)[C@@H](O)[C@H](O)O[C@@H]2CO)O[C@H](CO)[C@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O[C@]2(C(=O)O)C[C@H](O)[C@@H](NC(C)=O)[C@H]([C@H](O)[C@@H](CO)O[C@]3(C(=O)O)C[C@H](O)[C@@H](NC(C)=O)[C@H]([C@H](O)[C@H](O)CO)O3)O2)[C@H]1O

nearest known ligand 0.71

Predicted protein targets (top 5)

	gene	UniProt	supporting neighbours	confidence
▸	SIGLEC7	Q9Y286	6/20	0.71

▸	MAG	P20916	8/20	0.63

▸	SELP	P16109	2/20	0.61

▸	SELL	P14151	1/20	0.61

▸	SELE	P16581	3/20	0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL29615820	1.00	SIGLEC7 (0.71)	SIGLEC7MAGSELPSELLSELE
SCHEMBL31700314	0.97	SIGLEC7 (0.73)	SIGLEC7MAGSELPSELLSELE
SCHEMBL31700527	0.97	SIGLEC7 (0.73)	SIGLEC7MAGSELPSELLSELE
SCHEMBL29615858	0.97	SIGLEC7 (0.73)	SIGLEC7MAGSELPSELLSELE
SCHEMBL31179876	0.97	SIGLEC7 (0.73)	SIGLEC7MAGSELPSELLSELE
SCHEMBL29615728	0.97	SIGLEC7 (0.73)	SIGLEC7MAGSELPSELLSELE
SCHEMBL31716489	0.97	SIGLEC7 (0.70)	SIGLEC7MAGSELPSELLSELE
SCHEMBL29782338	0.97	SIGLEC7 (0.68)	SIGLEC7MAGSELPSELLSELE
SCHEMBL30427995	0.97	SIGLEC7 (0.68)	SIGLEC7MAGSELPSELLSELE
SCHEMBL30428234	0.96	MAG (0.68)	SIGLEC7MAGSELPSELLSELE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20250242035-A1	GLYCAN CONJUGATE COMPOSITIONS AND METHODS	GANNA BIO, INC.	2025-07-31	—	—	US	disclosed
EP-3341411-B1	ANTI-SIGLEC-7 ANTIBODIES AND METHODS OF USE THEREOF	ALECTOR LLC (US)	2025-06-11	—	—	EP	disclosed
US-20230035072-A1	METHODS OF USE OF ANTI-CD33 ANTIBODIES	ALECTOR LLC (US)	2023-02-02	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20250242035-A1	GLYCAN CONJUGATE COMPOSITIONS AND METHODS	SIGLEC7, SIGLEC9, ENGASE	SIGLEC7 1/4885MAG 343/4885SELP 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.